key: cord-0794906-14hweizh authors: Chi, Xiaojing; Zhang, Xinhui; Pan, Shengnan; Yu, Yanying; Lin, Tianli; Duan, Huarui; Liu, Xiuying; Chen, Wenfang; Yang, Xuehua; Ding, Qiang; Wang, Jianwei; Yang, Wei title: An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants date: 2021-12-25 journal: bioRxiv DOI: 10.1101/2021.12.25.474052 sha: 1f1c60252e173ad1fb39abd1d47f033fdd437e0f doc_id: 794906 cord_uid: 14hweizh The wide transmission and host adaptation of SARS-CoV-2 have led to the rapid accumulation of mutations, posing significant challenges to the effectiveness of vaccines and therapeutic antibodies. Although several neutralizing antibodies were authorized for emergency clinical use, convalescent patients derived natural antibodies are vulnerable to SARS-CoV-2 Spike mutation. Here, we describe the screen of a panel of SARS-CoV-2 receptor-binding domain (RBD) targeted nanobodies (Nbs) from a synthetic library and the design of a biparatopic Nb, named Nb1-Nb2, with tight affinity and super wide neutralization breadth against multiple SARS-CoV-2 variants of concern. Deep-mutational scanning experiments identify the potential binding epitopes of the Nbs on the RBD and demonstrate that biparatopic Nb1-Nb2 has a strong escape resistant feature against more than 60 tested RBD amino acid substitutions. Using pseudovirion-based and trans-complementation SARS-CoV-2 tools, we determine that the Nb1-Nb2 broadly neutralizes multiple SARS-CoV-2 variants, including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2), Lambda (C.37), Kappa (B.1.617.1) and Mu (B.1.621). Furthermore, a heavy chain antibody is constructed by fusing the human IgG1 Fc to Nb1-Nb2 (designated as Nb1-Nb2-Fc) to improve its neutralization potency, yield, stability and potential half-life extension. For the new Omicron variant (B.1.1.529) that harbors unprecedented multiple RBD mutations, Nb1-Nb2-Fc keeps a firm affinity (KD < 1.0×10−12 M) and strong neutralizing activity (IC50 = 0.0017 nM). Together, we developed a tetravalent biparatopic human heavy chain antibody with ultrapotent and broad-spectrum SARS-CoV-2 neutralization activity which highlights the potential clinical applications. In this study, we obtain several SARS-CoV-2 RBD targeting Nbs with either high-95 affinity or broad neutralization spectrum using a previously developed synthetic 96 nanobody discovery platform 10 . We identified a biparatopic Nb as the best in class 97 broadly neutralizing antibody, which can potently neutralize more than 60 SARS-CoV-98 2 Spike pseudotyped viruses bearing single point, combination, and deletion mutations, 99 as well as multiple VOC and VOI, including the new super mutant Omicron variant. Selection and design of neutralizing Nbs with potent activity and affinity. 106 The unceasing accumulation of mutations in the SARS-CoV-2 Spike causes the loss of 107 efficacy for some established neutralizing antibodies 26 . Iterative discovery and 108 identification of neutralizing antibodies against emerging variants will provide a solid 109 stockpile for global pandemic solutions. To isolate Nbs with potential neutralization 110 breadth, recombinant RBD antigens from strains P.1 (isolated from Brazil) and B.1.617 111 (isolated from India) were used to screen a fully synthetic and highly diversified Nb 112 phage display library 27 . After four rounds of reciprocal biopanning and phage ELISA, 113 a panel of Nb binders was obtained. Total 18 Nbs were expressed in Escherichia coli 114 and purified with one-step nickel affinity chromatography (Fig. 1a) . The sequences of 115 Nb complementary determining regions are listed in Table S1 . To evaluate the 116 neutralization breadth of these discovered Nbs, Spike-pseudotyped particle infection 117 assay from four SARS-CoV-2 variants (B. protective activity at 0.33 μM, and each of them acted with a unique neutralization 120 spectrum similarly or complementally (Fig. 1b) . Thermal stability analysis showed that 121 the Tm values range from 59.1 to 82.3 ℃, with most of them above 70 ℃ (Fig. 1b) . Nb multimerization strategy can dramatically enhance the affinity and neutralization 123 potency 28 . Thus, we designed a panel of homo-and hetero-dimeric Nbs by C-to N-124 terminus fusion expression with a flexible (GGGGS)5 linker sequence. Three Nbs (Nb1, 125 Nb2 and Nb15) with relatively broad neutralization spectrum were chose as monomeric 126 building blocks (Fig. 1c) . Most bivalent Nbs showed improved neutralization activity 127 against Delta variant-derived pseudovirus (Fig. 1d) Nb2 demonstrated high affinity (less than or near 0.001 nM) to all RBDs (Fig. 2) . These N354D and T393P. Decreases more than 100-fold also included E471Q, E484K/Q, general, the effect of mutations outside the RBD on the neutralization activity of the 162 monomeric Nbs is less than that inside the RBD region. However, in sharp contrast, the 163 bivalent Nb1-Nb2 exhibited an incredible neutralization spectrum width and enhanced 164 potency. Among 64 mutated constructs, neutralization potency of Nb1-Nb2 was 165 enhanced (2 to > 10-fold) in 46 of them, and a slight reduction (< 10-fold) was observed 166 only in 15 mutants (Fig. 3a) . The IC50 against various mutant pseudoviruses was 167 summarized in Fig. 3b . These data imply that neutralizing antibodies with escape 168 resistance can be designed by fusing two or more diverse Nbs. Based on the above mutation analysis, we predicted the possible RBD epitopes for Nb1 (Fig. 4a & Fig. S1 ). However, the monomeric Nbs showed much lower activities, 196 even loss of activity for Nb1 against Delta and Nb2 against Beta (Fig. 4a) . These 197 neutralization results were basically consistent with the affinity data (Fig. 2) . Generally, In addition, the thermal stability was also satisfied for the Nb1-Nb2-Fc (Fig. S3 ). variants of concern that we tested. Nb1-Nb2-Fc broadly neutralizes pseudotyped The primers for the specific mutation sites are in Table S2 . For the variants derived Table S3 . were measured, and percent neutralization was calculated. Neutralization efficiency 579 more than 90% was specified as Yes, 50%-90% as Yes/No, and less than 50% as No. Thermal stability of the purified Nbs were measured using circular dichroism spectra. Clinical features of patients infected with 2019 novel coronavirus in Wuhan A new coronavirus associated with human respiratory disease in China Experimental infection of domestic dogs and cats with SARS-479 CoV-2: Pathogenesis, transmission, and response to reexposure in cats SARS-CoV-2 exposure in wild white-tailed deer (Odocoileus 482 virginianus) Treatment of Coronavirus Disease 2019 (COVID-19): A 485 Review Molnupiravir: evidence by press release An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice An update of anti-viral treatment of Safety and immunogenicity of an rAd26 and rAd5 vector-based 494 heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-495 randomised phase 1/2 studies from Russia Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety Interim Analysis of 2 Randomized Clinical Trials Nebulised ALX-0171 for respiratory syncytial virus lower respiratory 533 tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, 534 phase 2b trial Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron 536 antigenic shift. bioRxiv Humanized single domain antibodies neutralize SARS-CoV-2 by targeting 538 the spike receptor binding domain Generation and Characterization of ALX-0171, a Potent Novel Therapeutic 541 Nanobody for the Treatment of Respiratory Syncytial Virus Infection Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-544 Binding Domain that Escape Antibody Recognition Geographic and Genomic Distribution of SARS-CoV-2 A novel cell culture system modeling the SARS-CoV-2 life cycle SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing 551 antibodies Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or 553 Coronavac vaccine recipients SARS-CoV-2 Omicron variant: Characteristics 555 and prevention The significant immune escape of pseudotyped SARS-CoV-2 variant 557 A neutralizing human antibody binds to the N-terminal domain of the Spike 562 protein of SARS-CoV-2 Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. 564 Tetravalent SARS-CoV-2 Neutralizing Antibodies Show Enhanced 566 Potency and Resistance to Escape Mutations a Schematic representation of the construction of Nb1-Nb2-Fc. Homology modeling of Nb1-Nb2-Fc was performed with SWISS-MODEL server. The structure is depicted as 632 surface mode. The CDR regions were colored as pink for Nb1 and blue for Nb2 Coomassie Blue staining of the Fc vector (lane 1) and Nb1-Nb2-Fc plasmid transfected 634 Lane 3 shows the affinity purified Nb1-Nb2-Fc. Fc fusion to 635 Nb1-Nb2 generates a heavy chain antibody with an approximate molecular weight of 636 60 kDa in reduced condition. c Neutralization of multiple SARS-CoV-2 GFP/ΔN trVLP 637 variants with Nb1-Nb2-Fc. d Summary of neutralization IC50 value of Fc-fused Nb that 638 was obtained in Fig. 5c. IC50 fold increases versus the corresponding non-Fc-fused 639 Neutralization of Omicron variant (B.1.1.529) Consensus sequence was derived from the Wuhan isolate (wt). b Affinity 644 analysis of four different Nbs against Omicron RBD with BLI. Fitted line plot showing 645 the binding kinetic of four Nbs with the immobilized Omicron RBD. c Neutralization 646 curve of Omicron pseudovirus by four Nbs. d Summary of binding kinetic and 647 neutralization activity of four Nbs against Omicron variant Screen and design of broad-spectrum neutralizing Nbs against SARS-CoV Binding affinity of Nbs against the RBDs from multiple circulating SARS Neutralization of SARS-CoV-2 VOC and VOI by monomeric and bivalent Neutralization of Omicron variant (B.1.1.529)